Business of Cannabis
Bedrocan, which for years has only supported external researchers financially, today announced the launching of its own Clinical Research Unit to conduct research into the effects of the cannabis products it produces on behalf of the Dutch government. Dutch cannabis researcher Matthijs Bossong will lead the Clinical Research Unit in Utrecht, Netherlands.
The Clinical Research Unit has long been a wish of Bedrocan’s Chief Scientific Officer Mikael Kowal: “Much research is being done worldwide with these products, but then other scientists decide what is being investigated. Now, we take the lead by conducting our own research.”
The first study has already been approved by a Medical Ethics Committee. Mikael: “We will take a closer look at two products: Bedrocan® and Bediol®. The study will determine the risk factors of cannabis use and hopefully serve as a guide to patients on how to use these products safely, i.e. in a way that does not cause anxiety or psychotic symptoms.”
Full report
https://businessofcannabis.com/bedrocan-opens-its-own-cannabis-clinical-research-unit/
